このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Percheron Therapeutics 将来の成長

Future 基準チェック /16

Percheron Therapeuticsの収益は年間32.3%で減少すると予測されていますが、年間収益は年間14.6%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に-12.5% 28.8%なると予測されています。

主要情報

-32.3%

収益成長率

-28.8%

EPS成長率

Pharmaceuticals 収益成長	34.6%
収益成長率	14.6%
将来の株主資本利益率	-12.5%
アナリストカバレッジ	Low
最終更新日	31 May 2024

今後の成長に関する最新情報

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26

業績と収益の成長予測

ASX:PER - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	4	-23	N/A	-14	1
6/30/2025	5	-31	N/A	-15	1
6/30/2024	4	-13	N/A	-16	1
12/31/2023	2	-11	-10	-10	N/A
9/30/2023	2	-11	-9	-9	N/A
6/30/2023	2	-11	-8	-8	N/A
3/31/2023	2	-10	-7	-7	N/A
12/31/2022	2	-8	-7	-7	N/A
9/30/2022	2	-7	-7	-7	N/A
6/30/2022	2	-6	-8	-8	N/A
3/31/2022	1	-7	-8	-8	N/A
12/31/2021	1	-9	-8	-8	N/A
9/30/2021	1	-9	-7	-7	N/A
6/30/2021	1	-8	-6	-6	N/A
3/31/2021	1	-6	-5	-5	N/A
12/31/2020	1	-4	-4	-4	N/A
9/30/2020	1	-5	-4	-4	N/A
6/30/2020	1	-6	-4	-4	N/A
3/31/2020	1	-6	-3	-3	N/A
12/31/2019	1	-6	-3	-3	N/A
9/30/2019	1	-4	-3	-3	N/A
6/30/2019	1	-3	-3	-3	N/A
3/31/2019	0	-3	-3	-3	N/A
12/31/2018	0	-3	-3	-3	N/A
9/30/2018	0	-3	-3	-3	N/A
6/30/2018	0	-2	-2	-2	N/A
3/31/2018	0	-2	-2	-2	N/A
12/31/2017	0	-2	-3	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-2	N/A	-2	N/A
12/31/2016	1	-2	N/A	-2	N/A
9/30/2016	2	-2	N/A	-2	N/A
6/30/2016	2	-3	N/A	-2	N/A
3/31/2016	3	-1	N/A	-1	N/A
12/31/2015	4	1	N/A	0	N/A
9/30/2015	5	1	N/A	1	N/A
6/30/2015	5	1	N/A	1	N/A
3/31/2015	3	-1	N/A	-1	N/A
12/31/2014	1	-3	N/A	-3	N/A
9/30/2014	1	-3	N/A	-3	N/A
6/30/2014	1	-3	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	1	-3	N/A	-2	N/A
9/30/2013	1	-3	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PER今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PER今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PER今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PERの収益 ( 14.6% ) Australian市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: PERの収益 ( 14.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PER 3 年以内に赤字になると予測されています。

Percheron Therapeutics 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

Consensus revenue estimates increase by 71%

Price target increased to AU$0.31

Price target increased to AU$0.31

Consensus forecasts updated

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Consensus EPS estimates upgraded to AU$0.022 loss

Price target increased by 7.1% to AU$0.30

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Antisense Therapeutics Limited, Annual General Meeting, Nov 15, 2023

Consensus revenue estimates increase by 71%

New minor risk - Financial data availability

New major risk - Financial position

New minor risk - Shareholder dilution

Antisense Therapeutics Limited Receives MHRA Approval for ATL1102 Phase IIb DMD Clinical Trial in UK

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Antisense Therapeutics Limited Announces the Appointment of James Garner as Chief Executive Officer, Effective 07 August 2023

Antisense Therapeutics Limited Receives Regulatory Authority Approval from the Turkish Medicines and Medical Device Agency

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Commences the Second Phase (Chronic Setting) of Its Program to Study the Effects of an Antisense Oligonucleotide (ASO) to CD49d (Mouse Equivalent of ATL1102) in a LGMDR2 Animal Model of Dysferlin Deficiency

Antisense Therapeutics Limited Reports Initial Positive Muscle Functional Data from A DMD

Antisense Therapeutics Limited Announces Clinical Trial Application Submit for ATL1102 Phase IIb DMD trial conduct in Europe

Less than half of directors are independent

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Retirement of Mark Diamond as Chief Executive Officer

Antisense Therapeutics Limited Initiates the Process with Contract Research Organisation Pharmaron

Antisense Therapeutics Limited, Annual General Meeting, Nov 17, 2022

Antisense Therapeutics Limited Announces Appointment of Anthony Filippis as Chief Commercial Officer

Price target increased to AU$0.31

Antisense Therapeutics Limited Announces Dosing Commenced in DMD Combination Therapy Study

Consensus forecasts updated

Antisense Therapeutics Limited Intends to Conduct Double-Blind, Placebo Controlled Six Month Dosing Trial of Atl1102 Followed by Six Month Open Label Phase

Full year 2022 earnings released: AU$0.009 loss per share (vs AU$0.015 loss in FY 2021)

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Antisense Therapeutics Limited Announces Long COVID-19 Study Identifies Novel Blood Markers as Potential Diagnostic and Therapeutic Targets

Antisense Therapeutics Limited Announces Outcomes from Its Collaboration to Study the Neurological Aspects of Long COVID-19

Antisense Therapeutics Limited Announces ATL1102 DMD Clinical Trial Application Submitted in Europe

Antisense Therapeutics Limited Announces Results from First Study of Antisense to CD49d in Limb Girdle Muscular Dystrophy R2 Mouse Model

Antisense Therapeutics Limited Announces the Results from A First Study of Antisense to CD49d in A Limb Girdle Muscular Dystrophy R2 (LGMDR2) Mouse Model

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Price target increased to AU$0.58

Antisense Therapeutics Limited Announces Dosing Commenced in MCRI Collaboration Animal Study

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Price target increased to AU$0.60

Antisense Therapeutics Limited Announces New Data Supports ATL1102s Broader Clinical Potential

Forecast to breakeven in 2024

Price target increased to AU$0.54

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Antisense Therapeutics Limited Announces US FDA Feedback on Type C Meeting for ATL1102 in the US

Antisense Therapeutics Limited Announces Manufacture of ATL1102 clinical supplies for Phase IIb trial

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Antisense Therapeutics Limited Announces the Paediatric Investigation Plan for ATL1102 in DMD Submitted to European Medicines Agency

Antisense Therapeutics Limited Announces Executive Changes

New 90-day high: AU$0.21

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Antisense Therapeutics Limited, Annual General Meeting, Dec 18, 2020

Antisense Therapeutics Limited Announces Statistically Significant Improvement in Pul2.0 with Atl1102 Treatment in Non-Ambulant Boys with DMD Compared to A Matched Natural History Control

An unknown buyer acquired a 49% stake in Antisense Therapeutics Limited (ASX:ANP) from Opthea Limited (ASX:OPT) for AUD 0.34 million.

Antisense Therapeutics Limited Auditor Raises 'Going Concern' Doubt

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘